Zoetis (zo-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees.
Role of Zoetis in the VAC2VAC project
Zoetis will provide scientific and technical input to the scientific work packages (Work Packages 1, 2, 3, and 4) as well as industry knowledge and expertise to Work Package 5 on validation. Industry regulatory knowledge and experience as well as global regulatory network access will be a key part of our contribution to Work Package 6, and we will provide overall project input through our role in Work Package 7.
Zoetis will also provide samples of vaccines/antigens for the assay development work that is the core part of Work Packages 1-4 and take part in relevant validation studies in Work Package 5. Zoetis brings a long history of industry experience to help ensure project success, assays and approaches that can be used in manufacturing and are acceptable to regulators to be developed.
This project is a unique chance to bring all stakeholders together to make real progress in this area and Zoetis is committed to its success.
Dr. Catrina Stirling is industry co-lead for the overall project representing the animal health sector and is part of the Steering Committee and Scientific Management Team as well as the veterinary industry co-lead for Work Package 6 (Regulatory).